Phase 2 Study of Brentuximab Vedotin Associated With CHP Followed by Consolidation With High-dose Therapy / Autologous Stem-cell Transplantation as Frontline Treatment of Patients With Enteropathy-associated T-cell Lymphoma Type 1.
Phase of Trial: Phase II
Latest Information Update: 16 Mar 2018
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Methylprednisolone; Prednisone
- Indications T-cell lymphoma
- Focus Therapeutic Use
- Acronyms EATL-001
- 13 Mar 2018 Status changed from not yet recruiting to recruiting.
- 03 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Nov 2017.
- 18 Jul 2017 New trial record